Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 03 okt 2008 - 10:11

Statutaire naam Crucell N.V.

Titel Crucell Receives NIAID/NIH Contract for Development of Ebola and Marburg Vaccines

Bericht Leiden, The Netherlands (October 3, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it received a National Institutes of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) contract aimed at advancing the development of a multivalent filovirus vaccine that includes both Ebola and Marburg viruses. The contract provides funding of up to $30 million, with additional options that may be triggered at the discretion of the NIH worth a further $40 million. "We are grateful to the NIAID/NIH for this award, which makes use of Crucell's proprietary AdVac® technology" said Dr. Jaap Goudsmit, Crucell's Chief Scientific Officer. "This award recognizes the scientific basis for using rare adenovirus serotypes to develop vaccines." Dr. Goudsmit added, "The contract builds upon earlier work Crucell has performed with the Vaccine Research Center at NIH, and brings us a step closer to being able to provide effective countermeasures against a highly lethal infectious disease." Crucell will be the primary contractor with additional services being supplied by the Southwest Foundation for Biomedical Research, located in San Antonio, Texas and Quintiles Guys Drug Research Unit, located in London. About Ebola and Marburg The Ebola and Marburg viruses are capable of causing hemorrhagic fever, a severe, often-fatal disease in humans characterized by high fever and massive internal bleeding causing death in 50% to 80% of all cases. Ebola and Marburg outbreaks occur regularly in tropical Africa, affecting both human and great ape populations. Since the Ebola virus was first recognized, approximately 2,200 cases including over 1,500 deaths have been reported. To date over 440 cases of Marburg have been reported with approximately 360 fatalities. Ebola and Marburg usually appear in sporadic outbreaks, and spread within a health-care setting. Because of the high disease-related mortality rates and lack of

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

200810030000000006_2008 - 1003 Crucell Receives NIAID-NIH Contract for Development of Ebola and Marburg Vaccines.pdf (opens in a new window)

Datum laatste update: 09 januari 2026